Pillstats
Rx only · Tablet, Film Coated · Oral

Abacavir Sulfate, Dolutegravir Sodium, Lamivudine

Brands: Triumeq · Abacavir Sulfate + Dolutegravir Sodium + Lamivudine

1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US1 NDCs
1 active makers
UKComing
soon
CAComing
soon
AUComing
soon
EUComing
soon
RxCUI (US)1433868
US makers1 labelers
Packages1
DEA / ScheduleNone

US acquisition costNADAC · per unit

Average across 1 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.

$37.41$74.82$112.23$149.64Jan 2026Jun 2026Jul 2026
$130.125
Latest avg · Jul 22, 2026
+0%
Since Jan 1, 2026
1
Active US suppliers
100%
Top-2 supplier share*

Medicaid dispensing volumeSDUD · per quarter

Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.

8.3K17K25K33K2025 Q12025 Q22025 Q32025 Q42026 Q1
20K
Rx · 2026 Q1
691K
Units dispensed
-32%
Rx vs. year ago
5
Quarters · since 2025 Q1

Who makes it1 active · 0 exited

US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.

LabelerTypePackagesStatus
ViiV Healthcare Companyunknown1SUPPLYING

Regulatory & supply eventsFDA · US

Shortages, recalls, and registration changes attached to this drug concept.

  • Mar 15, 2021
    RECALLRecall (Class II): Triumeq (abacavir, dolutegravir, and lamivudine) 600 mg/50 mg/300 mg Tablets 30 Tablets Rx Only NDC 49702-231-13 Manufa…

    CGMP Deviations: Intermittent exposure to temperature excursion during storage. — Recalling firm: Cardinal Health Inc. — FL, GA, SC